Silexion Therapeutics (SLXN) Stock Price, News & Analysis

Company Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $0.23 to $0.30
• 50-Day Range: $0.24 to $1.56
• 52-Week Range: $0.23 to $4.65
• Volume: 1.73 million shs
• Average Volume: 3.27 million shs
• Market Capitalization: $3.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

SLXN Stock Analysis - Frequently Asked Questions

How have SLXN shares performed this year?

Silexion Therapeutics' stock was trading at $1.47 at the beginning of 2024. Since then, SLXN stock has decreased by 83.5% and is now trading at $0.2420.
View the best growth stocks for 2024 here.

How were Silexion Therapeutics' earnings last quarter?

Silexion Therapeutics Corp (NASDAQ:SLXN) issued its quarterly earnings results on Thursday, August, 29th. The company reported ($5.87) earnings per share (EPS) for the quarter.

How do I buy shares of Silexion Therapeutics?

Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Silexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Last Earnings: 8/29/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 12/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Holding & other investment offices
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SLXN
• CUSIP: N/A
• CIK: 2022416
• Web: silexion.com
• Phone: 972-2-674-3430
• Fax: 212-572-6395
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.00
• High Stock Price Target: $1.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +313.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $260,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -32.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.06 per share
• Price / Cash Flow: 4.33
• Book Value: ($0.74) per share
• Price / Book: -0.33

Miscellaneous

• Outstanding Shares: 13,830,000
• Free Float: 9,265,000
• Market Cap: $3.35 million
• Optionable: N/A
• Beta: -0.19